Where the stock stands
Alkem Laboratories Ltd., a Healthcare stock, last traded at ₹5326.0 on September 24, 2026, down 1.69% from a previous close of ₹5417.5. That fall came on a day the Nifty itself slipped 1.64%, so the session's move was broadly in line with the wider market rather than a stock-specific break.
On valuation, the pack puts the price-to-earnings ratio at 29.56 and price-to-book at 4.61, with earnings per share of ₹180.2 and a dividend yield of 0.38%. Over longer windows the picture is flat: the stock is down about 2.23% over one year and roughly 0.13% over three months, while the one-month return is up about 0.92%.
What the smart-money flow shows
The evidence pack carries no smart-money data for this stock. There is no F&O positioning, no named bulk or block deal, no institutional buying or selling streak and no insider filing on record. The data therefore says nothing either way about how large investors are positioned here, and this section should be read as an absence of evidence rather than a signal.
The technical picture
The technical readings are computed off the September 23 close of ₹5417.5, one session before the latest price, so they do not yet reflect the 1.69% fall on September 24. On that basis the stock sat 8.7% below its 52-week high of ₹5933.5 and 7.26% above its 52-week low of ₹5051.0, which places it in the lower half of its yearly range. The one-week return to that close was about 4.68%.
The 14-day RSI (relative strength index, a momentum gauge that runs from 0 to 100) read 56.7, a middling level that points to neither stretched buying nor heavy selling. Relative volume was 0.96, meaning turnover was close to its usual level. The stock was trading below both its 50-day and 200-day simple moving averages, and neither a golden cross nor a death cross (the shorter average crossing above or below the longer one) was flagged.
Catalysts and what to watch
The main filings in the pack are resignations. Exchange filings dated July 23, July 24 and July 25, 2026 all carry the same text: the company informed the exchange of the resignation of Dr. Jitendra Singh Huda, with the role listed only as "Other", effective July 23, 2026. These appear to be repeated notices of a single event rather than three separate departures. A further NSE filing dated September 24, 2026 reports a resignation of a director, KMP or SMP, but the headline does not name the person or the role. The filings give no reason for either departure.
In the news flow, a headline from Univest reported the share price rising 3.03%, and Business Standard reported the stock spurting 2.36%, both roughly a week before the pack's date. A GuruFocus.com headline summarised the company's Q1 2027 earnings call as showing robust revenue growth; that is the publisher's description and the pack holds no reported figures to check it against.
What the data establishes: a price that has gone largely sideways over a year, a session decline that tracked the Nifty, technicals sitting below key moving averages, and resignation notices on file. What it does not establish is any smart-money view, a reason behind the resignations, or a single driver for the recent moves.